Tissue and plasma thioredoxin reductase expressions in patients with glioblastoma multiforme

Journal of Neurological Surgery, Part A: Central European Neurosurgery

Volumn 74, Issue 4, 2013, Pages 234-238

  Kemerdere, Rahsan ^a   Kacira, Tibet ^b   Hanimoglu, Hakan ^c   Kucur, Mine ^a   Tanriverdi, Taner ^a   Canbaz, Bulent ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ACIBADEM HOSPITAL   (Turkey)

^c BEZMIALEM VAKIF UNIVERSITY   (Turkey)

Author keywords

brain tumors; glioblastoma multiforme; thioredoxin reductase

Indexed keywords

THIOREDOXIN REDUCTASE;

ADULT; AGED; ARTICLE; BRAIN TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GLIOBLASTOMA; HUMAN; MALE; PROTEIN EXPRESSION; TISSUE LEVEL;

ADULT; AUTOPSY; FEMALE; GLIOBLASTOMA; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; THIOREDOXIN-DISULFIDE REDUCTASE;

EID: 84879610207     PISSN: 21936315     EISSN: 21936323     Source Type: Journal    
DOI: 10.1055/s-0032-1333422     Document Type: Article

References (32)

1. Louis D. N., Ohgaki H., Wiestler O. D., et al. The 2007 WHO Classification of Tumors of the Central Nervous System. Lyon, France IARC Press: 2007
2. CBTRUS 2008 statistical report: primary brain tumors in the United States, 1998-2002. Central Brain Tumor Registry of the United States, 2000-2004. Available at: http://www.cbtrus.org/reports/2007-2008/2007report.pdf. Accessed April 2012
3. Wen P. Y., Kesari S. Malignant gliomas in adults. N Engl J Med: 2008; 359 492 507
4. Saether C. A., Torsteinsen M., Torp S. H., et al. Did survival improve after the implementation of intraoperative neuronavigation and 3D ultrasound in glioblastoma surgery? A retrospective analysis of 192 primary operations. J Neurol Surg A Cent Eur Neurosurg: 2012; 73 73 78
5. Fisher J. L., Schwartzbaum J. A., Wrensch M., Wiemels J. L. Epidemiology of brain tumors. Neurol Clin: 2007; 25 867 890, vii (Pubitemid 47603275)
6. Wrensch M., Wiencke J. K., Wiemels J., et al. Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res: 2006; 66 4531 4541
7. Atukeren P., Kemerdere R., Kacira T., et al. Expressions of some vital molecules: glioblastoma multiforme versus normal tissues. Neurol Res: 2010; 32 492 501
8. Vitolo D., Paradiso P., Uccini S., Ruco L. P., Baroni C. D. Expression of adhesion molecules and extracellular matrix proteins in glioblastomas: relation to angiogenesis and spread. Histopathology: 1996; 28 521 528 (Pubitemid 26192947)
9. Chen T. C., Hinton D. R., Apuzzo M. LJ, Hofman F. M. Differential effects of tumor necrosis factor-alpha on proliferation, cell surface antigen expression, and cytokine interactions in malignant gliomas. Neurosurgery: 1993; 32 85 94 (Pubitemid 23020002)
10. Arnér E. SJ, Holmgren A. The thioredoxin system in cancer. Semin Cancer Biol: 2006; 16 420 426 (Pubitemid 44780139)
11. Söderberg A., Sahaf B., Rosén A. Thioredoxin reductase, a redox-active selenoprotein, is secreted by normal and neoplastic cells: presence in human plasma. Cancer Res: 2000; 60 2281 2289 (Pubitemid 30225195)
12. Powis G., Kirkpatrick D. L., Angulo M., Baker A. Thioredoxin redox control of cell growth and death and the effects of inhibitors. Chem Biol Interact: 1998; 111-112 23 34 (Pubitemid 28271931)
13. Welsh S. J., Bellamy W. T., Briehl M. M., Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res: 2002; 62 5089 5095 (Pubitemid 34984438)
14. Kakolyris S., Giatromanolaki A., Koukourakis M., et al. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res: 2001; 7 3087 3091 (Pubitemid 32963828)
15. Choi J. H., Kim T. N., Kim S., et al. Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. Anticancer Res: 2002; 22 3331 3335 (Pubitemid 36070110)
16. Biaglow J. E., Miller R. A. The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy. Cancer Biol Ther: 2005; 4 6 13 (Pubitemid 41350919)
17. Ford J. M., Seiferheld W., Alger J. R., et al. Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys: 2007; 69 831 838 (Pubitemid 47418404)
18. Ahmadi R., Urig S., Hartmann M., et al. Antiglioma activity of 2,2′:6′,2″-terpyridineplatinum(II) complexes in a rat model-effects on cellular redox metabolism. Free Radic Biol Med: 2006; 40 763 778 (Pubitemid 43327311)
19. Powis G., Montfort W. R. Properties and biological activities of thioredoxins. Annu Rev Pharmacol Toxicol: 2001; 41 261 295 (Pubitemid 32385890)
20. Nishinaka Y., Nakamura H., Masutani H., Yodoi J. Redox control of cellular function by thioredoxin; a new therapeutic direction in host defence. Arch Immunol Ther Exp (Warsz): 2001; 49 285 292 (Pubitemid 33612109)
21. Smart D. K., Ortiz K. L., Mattson D., et al. Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress. Cancer Res: 2004; 64 6716 6724 (Pubitemid 39297934)
22. Thelander L. Thioredoxin reductase. Characterization of a homogenous preparation from Escherichia coli B. J Biol Chem: 1967; 242 852 859
23. Zhang P., Liu B., Kang S. W., Seo M. S., Rhee S. G., Obeid L. M. Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bcl-2. J Biol Chem: 1997; 272 30615 30618 (Pubitemid 27527491)
24. Saitoh M., Nishitoh H., Fujii M., et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J: 1998; 17 2596 2606 (Pubitemid 28221195)
25. Yokomizo A., Ono M., Nanri H., et al. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res: 1995; 55 4293 4296
26. Raffel J., Bhattacharyya A. K., Gallegos A., et al. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med: 2003; 142 46 51 (Pubitemid 36934520)
27. Järvelä S., Bragge H., Paunu N., et al. Antioxidant enzymes in oligodendroglial brain tumors: association with proliferation, apoptotic activity and survival. J Neurooncol: 2006; 77 131 140
28. Haapasalo H., Kyläniemi M., Paunul N., Kinnula V. L., Soini Y. Expression of antioxidant enzymes in astrocytic brain tumors. Brain Pathol: 2003; 13 155 164 (Pubitemid 36460816)
29. Furnari F. B., Fenton T., Bachoo R. M., et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev: 2007; 21 2683 2710 (Pubitemid 350070717)
30. Chi A. S., Wen P. Y. Inhibiting kinases in malignant gliomas. Expert Opin Ther Targets: 2007; 11 473 496 (Pubitemid 46487596)
31. Sathornsumetee S., Rich J. N., Reardon D. A. Diagnosis and treatment of high-grade astrocytoma. Neurol Clin: 2007; 25 1111 1139, x (Pubitemid 47610809)
32. Sathornsumetee S., Reardon D. A., Desjardins A., Quinn J. A., Vredenburgh J. J., Rich J. N. Molecularly targeted therapy for malignant glioma. Cancer: 2007; 110 13 24